العلاج الكيميائي الفردي أو المعدل (تعديل الجرعة أو التأخير)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Source‎: Leuk Res 2011;35(8):991-7.

مفهرسة‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (يفتح نافذة جديدة)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (يفتح نافذة جديدة)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Source‎: Br J Haematol 2014;165(4):497-503.

مفهرسة‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (يفتح نافذة جديدة)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (يفتح نافذة جديدة)

Dainer PM, Knupp CL, Sartiano GP.

Source‎: Am J Hematol 1992;40(2):156-7.

مفهرسة‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (يفتح نافذة جديدة)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (يفتح نافذة جديدة)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Source‎: Lancet Oncol 2013;14(6):525-33.

مفهرسة‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (يفتح نافذة جديدة)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (يفتح نافذة جديدة)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Source‎: N Engl J Med 2020;383(7):617-29.

مفهرسة‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (يفتح نافذة جديدة)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (يفتح نافذة جديدة)

El Chaer F, Ballen KK

Source‎: Br J Haematol 2020;190(5):696-707.

مفهرسة‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (يفتح نافذة جديدة)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (يفتح نافذة جديدة)

Emadi A, Bade NA, Stevenson B, Singh Z.

Source‎: Pharmaceuticals (Basel) 2016;9(1):E12.

مفهرسة‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (يفتح نافذة جديدة)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (يفتح نافذة جديدة)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Source‎: J Clin Oncol 2009;27(28):4733-40.

مفهرسة‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (يفتح نافذة جديدة)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (يفتح نافذة جديدة)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Source‎: Int J Hematol 1997;65(4):415-6.

مفهرسة‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (يفتح نافذة جديدة)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (يفتح نافذة جديدة)

Garelius H, Grund S, Stockelberg D.

Source‎: Clin Case Rep 2015;3(5):287-90.

مفهرسة‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (يفتح نافذة جديدة)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (يفتح نافذة جديدة)

Juliusson G.

Source‎: Am J Hematol 1996;53(1):49.

مفهرسة‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (يفتح نافذة جديدة)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (يفتح نافذة جديدة)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Source‎: Eur J Haematol 2004;72(4):264-7.

مفهرسة‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (يفتح نافذة جديدة)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (يفتح نافذة جديدة)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Source‎: Am J Hematol 1996;51(3):251-2.

مفهرسة‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (يفتح نافذة جديدة)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (يفتح نافذة جديدة)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Source‎: Hematol Oncol 2014;32(1):40-6.

مفهرسة‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (يفتح نافذة جديدة)

Cytarabine dose for acute myeloid leukemia. (يفتح نافذة جديدة)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Source‎: N Engl J Med 2011;364(11):1027-36.

مفهرسة‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (يفتح نافذة جديدة)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (يفتح نافذة جديدة)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Source‎: Bone Marrow Transplant 2003;32(4):433-6.

مفهرسة‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (يفتح نافذة جديدة)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (يفتح نافذة جديدة)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Source‎: N Engl J Med. 2022;386(16):1519-31.

مفهرسة‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (يفتح نافذة جديدة)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (يفتح نافذة جديدة)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Source‎: Gynecol Oncol 2012;124(2):221-4.

مفهرسة‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (يفتح نافذة جديدة)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (يفتح نافذة جديدة)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Source‎: Leuk Res Rep. 2022 25;18:100355.

مفهرسة‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (يفتح نافذة جديدة)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (يفتح نافذة جديدة)

Norfolk DR, Wade P, Carter R.

Source‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (يفتح نافذة جديدة)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (يفتح نافذة جديدة)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Source‎: Leuk Lymphoma. 2019;60(9):2324-7.

مفهرسة‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (يفتح نافذة جديدة)

Hematopoietic growth factors: personalization of risks and benefits. (يفتح نافذة جديدة)

Puhalla S, Bhattacharya S, Davidson NE.

Source‎: Mol Oncol 2012;6(2):237-41.

مفهرسة‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (يفتح نافذة جديدة)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (يفتح نافذة جديدة)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Source‎: Leuk Lymphoma 2021;62(6):1497-501.

مفهرسة‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (يفتح نافذة جديدة)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (يفتح نافذة جديدة)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Source‎: Blood 2020;135(7):463-71.

مفهرسة‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (يفتح نافذة جديدة)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (يفتح نافذة جديدة)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Source‎: Bone Marrow Transplant 2005;36(8):715-20.

مفهرسة‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (يفتح نافذة جديدة)

A Mexican way to cope with stem cell grafting. (يفتح نافذة جديدة)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Source‎: Hematology 2012;17 Suppl 1:S195-7.

مفهرسة‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (يفتح نافذة جديدة)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (يفتح نافذة جديدة)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Source‎: Blood 2009;113(9):1875-91.

مفهرسة‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (يفتح نافذة جديدة)

SCT in Jehovah's Witnesses: the bloodless transplant. (يفتح نافذة جديدة)

Sloan JM, Ballen K.

Source‎: Bone Marrow Transplant 2008;41(10):837-44.

مفهرسة‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (يفتح نافذة جديدة)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (يفتح نافذة جديدة)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Source‎: Cancer 2006;107(8):1839-43.

مفهرسة‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (يفتح نافذة جديدة)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (يفتح نافذة جديدة)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Source‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

مفهرسة‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (يفتح نافذة جديدة)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (يفتح نافذة جديدة)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Source‎: Onco Targets Ther 2013;7:13-21.

مفهرسة‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (يفتح نافذة جديدة)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (يفتح نافذة جديدة)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Source‎: J Clin Oncol 2007;25(30):4722-9.

مفهرسة‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (يفتح نافذة جديدة)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (يفتح نافذة جديدة)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Source‎: Blood 2020;135(24):2137-45.

مفهرسة‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (يفتح نافذة جديدة)